v3.26.1
Other Investment (Tables)
 3 Months Ended
Mar. 31, 2026
Other Investment [Abstract]  
Schedule of Fair Value on a Recurring Basis and the Fair Value Hierarchy

The investment in Exousia Bio, Inc. is remeasured at fair value on a recurring basis. The following table presents the fair value hierarchy as of February 27, 2026 (initial recognition date) and March 31, 2026:

 

   Fair Value
as of
February 27,
2026		   Unrealized
Gain as of
March 31,
2026		   Fair Value
as of
March 31,
2026		 
             
Other Investment  $825,000   $175,000   $1,000,000 

 

  1. The fair value of the investment is classified as Level 1 in the fair value hierarchy under ASC 820, Fair Value Measurement, as it is based on quoted market prices in active markets for identical assets. Management notes that the existence of the lock-up and leak-out restrictions may affect the liquidity and ultimate realizable value of this investment, and will continue to reassess the fair value at each reporting date with any resulting unrealized gains or losses recognized in earnings consistent with ASC 321. Management concluded the contractual restrictions were specific to the holder and therefore did not affect the unit of account or Level 1 classification under ASC 820.